ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Nemus signs with Noramco for cannabinoid

by Rick Mullin
March 8, 2019 | APPEARED IN VOLUME 97, ISSUE 10

 

09710-buscon14-cvh.jpg

Nemus Bioscience has picked the controlled-substance manufacturing specialist Noramco to scale up production of cannabidiol-valine-hemisuccinate, a cannabidiol analog Nemus licensed from the University of Mississippi. The biotech firm says the analog is more bioavailable than cannabidiol as a treatment for ocular diseases. Meanwhile, Nemus hopes this year to begin clinical trials of a related product, tetrahydrocannabinol-valine-hemisuccinate, licensed from UM and produced by Albany Molecular Research for treating glaucoma.

X

Article:

This article has been sent to the following recipient:

Comments
Neal G. Anderson (ACS member no 00106127) (March 24, 2019 12:43 PM)
The structure of cannabidiol-valine-hemisuccinate is incorrect: need to excise the CO-CH2 next to the nitrogen. The isopropyl group of the valine unit should probably be drawn as bold / beta, as suggested by US20190031601A1, although that is not specified in the news releases that I have read.

Leave A Comment

*Required to comment